BPH relief made easier than ever before

Easy procedure

Simple and efficient procedure, performed in the urologist's office using a thin, flexible scope for delivery

less traumatic

Device is uniquely designed to permanently hold back the growing prostate without damaging tissue


We keep the patient at the center of everything we do, constantly innovating design to optimize safety & effectiveness

introducing the Spring® system

innovative design

The Spring® Implant is formed from a superelastic shape-memory material and is tailored to fit the unique geometry of the prostatic urethra. We designed the device to be easily and reliably deployed through a low-profile system under direct visualization, giving peace of mind to patients and urologists.

Clinically tested

Clinical cases performed by top global urologists have shown a well-tolerated procedure with a low rate of side effects, fast recovery, and durable results out to at least 2 years. We are currently enrolling patients in clinical trials in Australia, New Zealand, Canada, and Mexico.

OUR team

We have assembled a passionate and innovative team that brings extensive experience from successful startups and leading multinational medical device corporations. We believe that staying focused on the clinical need and challenging long-held industry assumptions will enable us to deliver superior results for patients.



Nick damiano

Co-founder & CEO

Nick is an experienced healthcare entrepreneur who has spent 12 years developing innovative medical device and digital health solutions. He earned his MS/BS from Stanford University and spent a year as a Stanford Biodesign Fellow.

shreya mehta


Shreya was the Thomas Fogarty Fellow at Stanford Biodesign and is an experienced medtech engineer. She earned an MS in Biomedical Engineering from University of Pittsburgh and spent four years as a lead reviewer at FDA.

ronald jabba


Ronald is an experienced executive who has spent 30 years in the medical device industry and has filed over 100 patents. He has brought many implantable devices to market and has exited four companies successfully.

supported by